. 2010 Aug 29;32(6):752–758. doi: 10.1007/s11096-010-9432-7

Table 1.

Concomitant use of cardiovascular and antidiabetic drugs among patients who had antiobesity drugs dispensed during 2004–2007

Group	Cardiovascular drugs^a		Antihypertensives^b		Lipid modifying agents^c		Drugs used in diabetes^d		Total concomitant drug use^e
Group	n	%	n	%	n	%	n	%	n	%
Total study population	28,445	34.0	25,128	30.0	12,235	14.6	6,520	7.8	69,496	83.0
Gender
Men	8,212	45.7	7,261	40.4	4,386	24.4	2,286	12.7	14,270	79.4
Women	20,233	30.8	17,867	27.2	7,849	11.9	4,234	6.4	55,226	84.0
Age (years)
0–29	611	4.7	517	4.0	126	1.0	413	3.2	9,682	74.8
30–59	19,283	32.7	16,862	28.6	7,666	13.0	4,364	7.4	48,590	82.4
60–99	8,551	72.6	7,749	65.8	4,443	37.7	1,743	14.8	11,224	95.3
No. of prescriptions of antiobesity drugs
1	5,896	28.2	5,111	24.5	2,569	12.3	1,299	6.2	15,039	72.0
>1	22,549	35.9	20,017	31.9	9,666	15.4	5,221	8.3	54,457	86.7
Amount of antiobesity drugs dispensed (DDD/year)
<290	14,520	37.8	12,929	33.7	6,182	16.1	3,195	8.3	34,222	89.2
290–360	6,382	32.7	5,631	28.8	2,787	14.3	1,601	8.2	16,097	82.4
>360	1,647	33.6	1,457	29.7	697	14.2	425	8.7	4,138	84.3

^aATC group C

^bATC group C02, C03, C07, C08 and C09

^cATC group C10

^dATC group A10

^eAny drug except antiobesity drugs